PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18695886-0 2008 BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Lovastatin 48-58 cyclin dependent kinase inhibitor 1A Homo sapiens 92-104 25605247-4 2015 Here we present evidence that lovastatin can induce the degradation of Skp2, a subunit of the SCFSkp2 ubiquitin ligase that targets p27Kip1 and p21Cip1 for proteasomal destruction. Lovastatin 30-40 cyclin dependent kinase inhibitor 1A Homo sapiens 144-151 18695886-7 2008 Additionally, the mRNA and protein expression of cyclin D1, cyclin-dependent kinase 4 (CDK4) and retinoblastoma protein (pRb), was further down-regulated under exposure to lovastatin in condition of BRCA1 overexpression, but the expression of p21WAF1/CIP1, a cyclin-dependent kinase inhibitor (CDKI), was further up-regulated, both in vitro and in vivo detected with quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis. Lovastatin 172-182 cyclin dependent kinase inhibitor 1A Homo sapiens 243-255 18695886-9 2008 Our results suggest that BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway, which will provide an innovative experimental framework to study control of breast cancer cell proliferation. Lovastatin 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 117-129 18188523-5 2008 The proportion of cells in G0/G1 phase, apoptosis and p21 protein expression increased after lovastatin alone or combined with 4-Gy irradiation in both cell lines. Lovastatin 93-103 cyclin dependent kinase inhibitor 1A Homo sapiens 54-57 17158337-4 2007 Lovastatin specifically recruits the forkhead box FoxO3a transcription factor to the p21 promoter, mediating transcriptional transactivation of the p21 gene as analyzed in isolated primary cardiomyocytes. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 85-88 17158337-5 2007 Lovastatin also stimulates protein kinase B/Akt kinase activity, and Akt-dependent phosphorylation forces p21 in the cytoplasm, where it inhibits Rho-kinases contributing to the suppression of cardiomyocyte hypertrophy. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 106-109 17158337-6 2007 Loss of p21 or FoxO3a by RNA interference causes a general inhibition of lovastatin signal transduction. Lovastatin 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 8-11 17158337-4 2007 Lovastatin specifically recruits the forkhead box FoxO3a transcription factor to the p21 promoter, mediating transcriptional transactivation of the p21 gene as analyzed in isolated primary cardiomyocytes. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 148-151 10393901-1 1999 In this paper we present the finding that lovastatin arrests cells by inhibiting the proteasome, which results in the accumulation of p21 and p27, leading to G1 arrest. Lovastatin 42-52 cyclin dependent kinase inhibitor 1A Homo sapiens 134-137 16424040-7 2006 Cells devoid of p21 were refractory to the growth-inhibitory activity of lovastatin, FTI-277, and GGTI-298. Lovastatin 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 16-19 10393901-3 1999 Previously, we reported that lovastatin can be used to arrest cultured cells in the G1 phase of the cell cycle, resulting in the stabilization of the cyclin-dependent kinase inhibitors (CKIs) p21 and p27. Lovastatin 29-39 cyclin dependent kinase inhibitor 1A Homo sapiens 192-195 10393901-4 1999 In this report we show that this stabilization of p21 and p27 may be the result of a previously unknown function of the pro-drug, beta-lactone ring form of lovastatin to inhibit the proteasome degradation of these CKIs. Lovastatin 156-166 cyclin dependent kinase inhibitor 1A Homo sapiens 50-53 9864387-0 1999 Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 27-31 9553123-4 1998 Lovastatin treatment increased protein and mRNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1), increased binding of p21 with Cdk2, markedly inhibited cyclin E- and Cdk2-associated phosphorylation of histone H1 or GST-retinoblastoma protein, enhanced binding of the retinoblastoma protein to the transcription factor E2F-1 in vivo, and induced the activation of a p21 promoter reporter construct. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 96-99 9553123-4 1998 Lovastatin treatment increased protein and mRNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1), increased binding of p21 with Cdk2, markedly inhibited cyclin E- and Cdk2-associated phosphorylation of histone H1 or GST-retinoblastoma protein, enhanced binding of the retinoblastoma protein to the transcription factor E2F-1 in vivo, and induced the activation of a p21 promoter reporter construct. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 100-109 9553123-4 1998 Lovastatin treatment increased protein and mRNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1), increased binding of p21 with Cdk2, markedly inhibited cyclin E- and Cdk2-associated phosphorylation of histone H1 or GST-retinoblastoma protein, enhanced binding of the retinoblastoma protein to the transcription factor E2F-1 in vivo, and induced the activation of a p21 promoter reporter construct. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 133-136 9553123-4 1998 Lovastatin treatment increased protein and mRNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1), increased binding of p21 with Cdk2, markedly inhibited cyclin E- and Cdk2-associated phosphorylation of histone H1 or GST-retinoblastoma protein, enhanced binding of the retinoblastoma protein to the transcription factor E2F-1 in vivo, and induced the activation of a p21 promoter reporter construct. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 133-136 9553123-5 1998 By using p21 promoter deletion constructs, the lovastatin-responsive element was mapped to a region between -93 and -64 relative to the transcription start site. Lovastatin 47-57 cyclin dependent kinase inhibitor 1A Homo sapiens 9-12 31821701-5 2020 Lovastatin caused p21 elevation while reduced cyclin D1 and survivin levels. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 9044834-5 1997 Synchronization of tumor cells by lovastatin, which arrests cells in G1, resulted in increased levels of p21 and p27 with a concomitant decrease in cyclin-dependent kinase 2-associated kinase activity. Lovastatin 34-44 cyclin dependent kinase inhibitor 1A Homo sapiens 105-108 31821701-9 2020 Lovastatin"s enhancing effects on p53 activation, p21 elevation and survivin reduction were significantly reduced in the presence of p38MAPK signalling inhibitor. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 50-53 27122225-11 2016 Moreover, transfection of cells with AMPK dominant negative mutant (AMPK-DN), HDAC3, HDAC4 or p63 siRNA significantly reduced lovastatin"s effects on p21(cip/Waf1) and survivin. Lovastatin 126-136 cyclin dependent kinase inhibitor 1A Homo sapiens 150-153 27122225-5 2016 Lovastatin increased p21(cip/Waf1) level while the survivin level was decreased in the presence of lovastatin. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 21-24 27122225-5 2016 Lovastatin increased p21(cip/Waf1) level while the survivin level was decreased in the presence of lovastatin. Lovastatin 0-10 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 27122225-11 2016 Moreover, transfection of cells with AMPK dominant negative mutant (AMPK-DN), HDAC3, HDAC4 or p63 siRNA significantly reduced lovastatin"s effects on p21(cip/Waf1) and survivin. Lovastatin 126-136 cyclin dependent kinase inhibitor 1A Homo sapiens 158-162